The FDA has approved the sale of C.R. Bard‘s new Agento™ silver coated endotracheal tube. The company, though, is awaiting publication of results of a peer reviewed clinical trial of the device in one of the major medical journals, before putting the product on the market. C.R. Bard is keeping somewhat tight lipped about the Agento™, and told Medgadget they will wait to start marketing the device before releasing any photos of it.
From the press release:
The [FDA] clearance includes claims for the reduction of microbiologically confirmed ventilator associated pneumonia (VAP). Management is currently evaluating the benefits of launching the Agento(TM) IC product in conjunction with the potential publication of the clinical trial results in a major peer-review medical journal. The product will be marketed by Bard’s Medical division located in Covington, Georgia.
VAP is one of the most costly hospital acquired infections and is associated with high patient mortality and morbidity. It is especially prevalent in hospital intensive care units in cases where a ventilated patient has an endotracheal tube in place for more than 24 hours. The Agento(TM) IC product incorporates Bard’s proprietary silver colloid polymer technology which allows the tube to elute microbicidal levels of silver ions.